NIKI logo

NIKI BIOSOLUTIONS INC

NIKINASDAQ
🏆 #5141 by market capUS Equity
$182.94▲ $0.90 (+0.49%)
Simulated price
🔔
Track NIKI
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.5%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$6M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
7.1%
Thin
💵FCF Margin
—
⚖️P/S Ratio
4.8x
Fair
Otter Score
56
Weak
No chart data available for NIKI.

Trading Snapshot

Day Range
$180.85 – $183.76
52-Week Range
$4.52 – $12.24
Volume
$2.55B
Avg Volume
$2.99B
Shares Outstanding
3.6M
Next Earnings
Dec 3, 2026

Fundamentals Snapshot

Annual Revenue
$1M
Last Q Revenue
$285,377
P/E Ratio
—
P/S Ratio
4.8x
EPS (TTM)
$-3.54
Dividend Yield
—
Dilution (1yr)
+16.9%

Why Investors Own NIKI

  • ✓High-growth profile — revenue up +24.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 25% gross margin and 21% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NIKI logo

NIKI BIOSOLUTIONS INC

NIKI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
2.4%▼ −60.4% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$2M▼ −52.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$2M▲ +54.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
74K▲ +16.9% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$10K▲ +$2M YoY
StockOtter · stockotter.space

About NIKI BIOSOLUTIONS INC

Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans from treatments for diseases with unmet medical needs, particularly in oncology and infectious diseases, to the development of innovative, blood-based diagnostic tests for brain health and other conditions.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$190.37
▲ +4.1% Upside
High Target$228.56
Low Target$170.45
Based on 13 analysts

Latest News & Updates

🚀
CNBC·2h ago

NIKI BIOSOLUTIONS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift NIKI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

NIKI BIOSOLUTIONS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.